Sexual health and emotional wellbeing of patients with haematological malignancies: general review.

Sexual health is an important aspect of a person's life. Many patients and haematologists believe that intimacy and sexuality issues are substantial during cancer treatment. The haematological cancer disease, diagnosis, shock of the announcement, treatment, and follow-up appointments, can all have negative effects on the quality of life of patients, their partners, other family members, and friends. Addressing the intimate aspects of patients' lives not only enhances their wellbeing but also contributes to the quality of their survivorship. Progress has been made in the management of sexual life-related complications; however, novel strategies in coordination with a multidisciplinary team need to be implemented. New and comprehensive approaches must be developed on a multidisciplinary scale. In this Series paper, we discuss the factors affecting the sexual life of patients with haematological malignancies, different methods to assess sexual function, as well as management approaches of sexual wellbeing among patients with haematological cancers.

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Déclaration de conflit d'intérêts

Declaration of interests TA declares consulting fees from Biotest and Amgen; received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Biotest; received meeting and travel support from Biotest, Sandoz, Novartis, Astellas Pharma, and Viatris; is a member of Société Francophone de Greffe de Moelle et de Thérapie Cellulaire; and is responsible of practice harmonisation group and committee for the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (unpaid). MM declares grants or contracts (out the present manuscript) from Sanofi, Novartis, and Janssen; received consulting fees from Adaptive Biotechnologies, Amgen, Astellas, Bristol-Myers Squibb, GSK, Janssen, Jazz, Novartis, Pfizer, Sanofi, Stemline, and Takeda; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Adaptive Biotechnologies, Amgen, Astellas, Bristol-Myers Squibb, GSK, Janssen, Jazz, Novartis, Pfizer, Sanofi, Stemline, Takeda, and MaaT; was a participant of a Data Safety Monitoring Board and Advisory Board for Janssen; has a leadership and fiduciary role in other board, society, committee, and advocacy group, (unpaid) for European Society for Blood and Marrow Transplantation and International Academy for Clinical Hematology. EB declares consulting fees from Pfizer and Astellas; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Astellas, Alexion, Jazz Pharmaceuticals, Gilead, MSD, Keocyt, Amgen, Beigen, Pierre Fabre, Pfizer, Celgene/Bristol-Myers Squibb, and Sanofi; declared support for attending meetings and travel from Jazz Pharmaceuticals, Gilead, and Novartis. All other authors declare no competing interests.